# A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

> **NCT03945721** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 21 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Residual Disease

## Interventions

- **DRUG:** Niraparib
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03945721
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945721, "A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03945721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*